109
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Immunodeficiency, auto-inflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency

      research-article
      1 , 2 , 1 , 3 , 4 ,   5 , 1 , 6 , 7 , 1 , 1 , 5 , 8 , 6 , 7 , 6 , 7 , 9 , 10 , 3 , 3 , 11 , 8 , 12 , 13 , 14 , 7 , 9 , 7 , 10 , 7 , 15 , 5 , 4 , 5 , 16 , 6 , 7 , 2 , 1 , 6 , 7 , 10 , 6 , 7 , 10 , 17
      Nature immunology

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We report the clinical description and molecular dissection of a new fatal human inherited disorder characterized by chronic auto-inflammation, invasive bacterial infections and muscular amylopectinosis. Patients from two kindreds carried biallelic loss-of-expression and loss-of-function mutations in HOIL1, a component the linear ubiquitination chain assembly complex (LUBAC). These mutations resulted in impairment of LUBAC stability. NF-κB activation in response to interleukin-1β (IL-1β) was compromised in the patients’ fibroblasts. By contrast, the patients’ mononuclear leukocytes, particularly monocytes, were hyperresponsive to IL-1β. The consequences of human HOIL-1 and LUBAC deficiencies for IL-1β responses thus differed between cell types, consistent with the unique association of auto-inflammation and immunodeficiency in these patients. These data suggest that LUBAC regulates NF-κB-dependent IL-1β responses differently in different cell types.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis.

          SHARPIN is a ubiquitin-binding and ubiquitin-like-domain-containing protein which, when mutated in mice, results in immune system disorders and multi-organ inflammation. Here we report that SHARPIN functions as a novel component of the linear ubiquitin chain assembly complex (LUBAC) and that the absence of SHARPIN causes dysregulation of NF-κB and apoptotic signalling pathways, explaining the severe phenotypes displayed by chronic proliferative dermatitis (cpdm) in SHARPIN-deficient mice. Upon binding to the LUBAC subunit HOIP (also known as RNF31), SHARPIN stimulates the formation of linear ubiquitin chains in vitro and in vivo. Coexpression of SHARPIN and HOIP promotes linear ubiquitination of NEMO (also known as IKBKG), an adaptor of the IκB kinases (IKKs) and subsequent activation of NF-κB signalling, whereas SHARPIN deficiency in mice causes an impaired activation of the IKK complex and NF-κB in B cells, macrophages and mouse embryonic fibroblasts (MEFs). This effect is further enhanced upon concurrent downregulation of HOIL-1L (also known as RBCK1), another HOIP-binding component of LUBAC. In addition, SHARPIN deficiency leads to rapid cell death upon tumour-necrosis factor α (TNF-α) stimulation via FADD- and caspase-8-dependent pathways. SHARPIN thus activates NF-κB and inhibits apoptosis via distinct pathways in vivo.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex.

            Cpdm (chronic proliferative dermatitis) mice develop chronic dermatitis and an immunodeficiency with increased serum IgM, symptoms that resemble those of patients with X-linked hyper-IgM syndrome and hypohydrotic ectodermal dysplasia (XHM-ED), which is caused by mutations in NEMO (NF-κB essential modulator; also known as IKBKG). Spontaneous null mutations in the Sharpin (SHANK-associated RH domain interacting protein in postsynaptic density) gene are responsible for the cpdm phenotype in mice. SHARPIN shows significant similarity to HOIL-1L (also known as RBCK1), a component of linear ubiquitin chain assembly complex (LUBAC), which induces NF-κB activation through conjugation of linear polyubiquitin chains to NEMO. Here, we identify SHARPIN as an additional component of LUBAC. SHARPIN-containing complexes can linearly ubiquitinate NEMO and activated NF-κB. Thus, we re-define LUBAC as a complex containing SHARPIN, HOIL-1L, and HOIP (also known as RNF31). Deletion of SHARPIN drastically reduced the amount of LUBAC, which resulted in attenuated TNF-α- and CD40-mediated activation of NF-κB in mouse embryonic fibroblasts (MEFs) or B cells from cpdm mice. Considering the pleomorphic phenotype of cpdm mice, these results confirm the predicted role of LUBAC-mediated linear polyubiquitination in NF-κB activation induced by various stimuli, and strongly suggest the involvement of LUBAC-induced NF-κB activation in various disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.

              Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone. We studied nine children from six families who had neonatal onset of sterile multifocal osteomyelitis, periostitis, and pustulosis. Response to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first patient prompted us to test for the presence of mutations and changes in proteins and their function in interleukin-1-pathway genes including IL1RN. We identified homozygous mutations of IL1RN in nine affected children, from one family from Newfoundland, Canada, three families from The Netherlands, and one consanguineous family from Lebanon. A nonconsanguineous patient from Puerto Rico was homozygous for a genomic deletion that includes IL1RN and five other interleukin-1-family members. At least three of the mutations are founder mutations; heterozygous carriers were asymptomatic, with no cytokine abnormalities in vitro. The IL1RN mutations resulted in a truncated protein that is not secreted, thereby rendering cells hyperresponsive to interleukin-1beta stimulation. Patients treated with anakinra responded rapidly. We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote this autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN. The absence of interleukin-1-receptor antagonist allows unopposed action of interleukin-1, resulting in life-threatening systemic inflammation with skin and bone involvement. (ClinicalTrials.gov number, NCT00059748.) 2009 Massachusetts Medical Society
                Bookmark

                Author and article information

                Journal
                100941354
                21750
                Nat Immunol
                Nat. Immunol.
                Nature immunology
                1529-2908
                1529-2916
                10 October 2012
                28 October 2012
                December 2012
                01 June 2013
                : 13
                : 12
                : 1178-1186
                Affiliations
                [1 ]St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, NY, USA
                [2 ]Laboratory of Molecular Signaling and Cell Activation, CNRS, URA 2582, Institut Pasteur, Paris, France, EU
                [3 ]Laboratory of Genetic Disorders of Childhood and Pediatric Clinic, A. Nocivelli Institute for Molecular Medicine, Dept of Pathology, Spedali Civili and Pediatric Clinic, University of Brescia, Brescia, Italy, EU
                [4 ]Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
                [5 ]Baylor Institute for Immunology Research and Baylor Research Institute, Dallas, Texas, USA
                [6 ]Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U980, Necker Medical School, Paris, France, EU
                [7 ]Paris Descartes University, Sorbonne Paris Cité, France, EU
                [8 ]Washington University School of Medicine and Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, Saint Louis, Missouri, USA
                [9 ]Reference Center for Complex Congenital Heart Defects, Assistance Publique Hôpitaux de Paris (AP-HP), Necker Enfants Malades Hospital, Paris, France, EU
                [10 ]Pediatric Hematology-Immunology-Rheumatology Unit, AP-HP, Necker Enfants Malades Hospital, Paris, France, EU
                [11 ]Institut Pasteur, Structural and Cellular Biochemistry Unit, CNRS, URA 2185, France, EU
                [12 ]Experimental Laboratory Immunology, Department of Microbiology and Immunology, Biomedical Science Group, Catholic University of Leuven, Leuven, Belgium, EU
                [13 ]Pathology Laboratory, AP-HP, Raymond Poincarré, Garches, France, EU
                [14 ]Department of Pathology, Spedali Civili and University of Brescia, Brescia, Italy, EU
                [15 ]Pathology Laboratory, AP-HP, Necker Enfants Malades Hospital, Paris, France, EU
                [16 ]Division of Immunology and The Manton Center for Orphan Disease Research, Children’s Hospital, Harvard Medical School, Boston, MA, USA
                [17 ]Study Center for Primary Immunodeficiencies, AP-HP, Necker Enfants Malades Hospital, Paris, France, EU
                Author notes
                [*, #, **, ##]

                these authors contributed equally to this work

                Article
                NIHMS410086
                10.1038/ni.2457
                3514453
                23104095
                b075ea29-0ab7-4ba8-9ad3-63f19b254d94

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
                Award ID: R01 AR050770 || AR
                Categories
                Article

                Immunology
                Immunology

                Comments

                Comment on this article